Award
NIH Reporter #11405296
A Phase 2a Clinical Trail With a Drug that Targets CD40 Mediated Autoinflammation.
Recipient
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Award Amount
$635,040.00
Ceiling
$635,040.00
Awarded
August 26, 2026
Identifier
11405296
This award funds a Phase 2a clinical trial for a drug targeting CD40-mediated autoinflammation in type 1 diabetes, including preclinical and safety testing, to assess efficacy and biomarkers.
Description
The project involves a clinical trial testing a drug targeting CD40 for autoimmune inflammation in type 1 diabetes. The project includes preclinical work, safety testing, and a Phase 2a clinical trial. It aims to evaluate efficacy, safety, and biomarkers such as C-peptide, Th40 cells, and inflammatory cytokines.